Altimmune, Inc. — Director's Dealing 2023

Feb 6, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Altimmune, Inc. (ALT)
CIK: 0001326190
Period of Report: 2023-02-02

Reporting Person: Garg Vipin K (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-02-02	Common Stock, par value $0.0001	M	18950	—	Acquired	257551	Direct
2023-02-02	Common Stock, par value $0.0001	F	8422	$15.04	Disposed	249129	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-02-02	Restricted Stock Units	$	M	18950	Disposed		Common Stock, par value $0.0001 (18950)	Direct

Footnotes

F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested.

F2: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs.

F3: The RSUs become vested in substantially equal annual installments over the 4 years following February 2, 2022, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date.